Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Innate Pharma Logo
Innate Pharma Growth Score
50
CB Rank
42452
Heat Score
55
Innate Pharma is a biopharmaceutical company developing immunotherapy drug candidates for the treatment of cancer and inflammatory diseases.
Founded
obfuscation
PublicPost-IPO Equity Marseille, Provence-Alpes-Cote d'Azur, France101-250 www.innate-pharma.com/
Biopharma
Biotechnology
Clinical Trials
Medical
Pharmaceutical
Overview

Innate Pharma
Total Funding
obfuscation
Growth Score
50
Heat Score
55

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score50
-3 pts
in past quarter
Heat Score 55
2 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Innate Pharma

CB Rank
42452
Innate Pharma is a biopharmaceutical company developing immunotherapy drug candidates for the treatment of cancer and inflammatory diseases.
Founded
obfuscation
PublicPost-IPO Equity Marseille, Provence-Alpes-Cote d'Azur, France101-250 www.innate-pharma.com/
Biopharma
Biotechnology
Clinical Trials
Medical
Pharmaceutical

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation
Post-IPO Secondary
OBF
in
obfuscation

Key People

Details

Legal Name Innate Pharma S.A.
Operating Status Active
Stock Symbol  EPA:IPH
Company Type For Profit
Founders  Alessandro Moretta, Eric Vivier, François Romagne, Hervé Brailly, Jean Fournie, Marc Bonneville
About the Company

Innate Pharma S.A. is a biopharmaceutical company developing first-in-class immunotherapy drug candidates for cancer and inflammatory diseases.

The Company specializes in the development of novel monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Its innovative approaches have led to

licensing agreements with Novo Nordisk A/S and Bristol-Myers Squibb.

Phone Number +33 (0)4 30 30 30 30
Predictions & Insights

Growth Insight

See this Growth Insight
Innate Pharma is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Products & Services

Monalizumab
An immunotherapy drug candidate targeting the NKG2A receptor to enhance immune response against cancer cells.
IPH4102
A monoclonal antibody targeting KIR3DL2 receptor for the treatment of certain T-cell lymphomas.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 10
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Innate Pharma Logo
Post-IPO Equity - Innate Pharma
1
obfuscation
SanofiPost-IPO Equity
obfuscation
Post-IPO Equity - Innate Pharma Logo
Post-IPO Equity - Innate Pharma
1
obfuscation
SanofiPost-IPO Equity
obfuscation
Post-IPO Equity - Innate Pharma Logo
Post-IPO Equity - Innate Pharma
1
obfuscation
SanofiPost-IPO Equity
obfuscation
Post-IPO Equity - Innate Pharma Logo
Post-IPO Equity - Innate Pharma
1
obfuscation
SanofiPost-IPO Equity
obfuscation
Post-IPO Equity - Innate Pharma Logo
Post-IPO Equity - Innate Pharma
1
obfuscation
SanofiPost-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 10
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Innate Pharma Logo
Post-IPO Equity - Innate Pharma
1
obfuscation
SanofiPost-IPO Equity
obfuscation
Post-IPO Equity - Innate Pharma Logo
Post-IPO Equity - Innate Pharma
1
obfuscation
SanofiPost-IPO Equity
obfuscation
Post-IPO Equity - Innate Pharma Logo
Post-IPO Equity - Innate Pharma
1
obfuscation
SanofiPost-IPO Equity
obfuscation
Post-IPO Equity - Innate Pharma Logo
Post-IPO Equity - Innate Pharma
1
obfuscation
SanofiPost-IPO Equity
obfuscation
Post-IPO Equity - Innate Pharma Logo
Post-IPO Equity - Innate Pharma
1
obfuscation
SanofiPost-IPO Equity

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
Sanofi Logo
Sanofi
Yes
Post-IPO Equity - Innate Pharma Logo
Post-IPO Equity - Innate Pharma
—
Sanofi Logo
Sanofi
Yes
Post-IPO Equity - Innate Pharma Logo
Post-IPO Equity - Innate Pharma
—
Sanofi Logo
Sanofi
Yes
Post-IPO Equity - Innate Pharma Logo
Post-IPO Equity - Innate Pharma
—
Sanofi Logo
Sanofi
Yes
Post-IPO Equity - Innate Pharma Logo
Post-IPO Equity - Innate Pharma
—
Sanofi Logo
Sanofi
Yes
Post-IPO Equity - Innate Pharma Logo
Post-IPO Equity - Innate Pharma
—
Market Intelligence
People
View Profiles & Contacts
Headcount 101-250 Employee Profiles 13 Board Members and Advisors 1 Contacts 81

Employee Profiles

Board Members and Advisors

News

News and Press

News•Jun 3, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 18, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 13, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 13, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

4,084
104%
 in past month

IT Spend

$401.9KThis year, Innate Pharma is projected to spend $401.9K on IT, according to Aberdeen.

Interest Signals

TopicSurge Score
Corporate gifting Logo
Corporate gifting
82

Actively Used Products

16Innate Pharma uses 16 technology products and services including HTML5, Microsoft Outlook, and  Bootstrap, according to G2 Stack.

Active Website Tech Count

5Innate Pharma is actively using 5 technologies for its website, according to BuiltWith. These include IPhone / Mobile Compatible, Google Tag Manager, and  Google Font API.

Total IP

63The intellectual property of Innate Pharma includes 61 registered patents primarily in the 'Organic Chemistry' category, according to IPqwery. Additionally, Innate Pharma has registered 2 trademarks with the most popular class being 'Pharmaceutical, veterinary and sanitary products', according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Innate Pharma's headquarters? Innate Pharma is located in Marseille, Provence-Alpes-Cote d'Azur, France.Who invested in Innate Pharma? Innate Pharma has 16 investors including Sanofi and  Institute for Follicular Lymphoma Innovation.When was the last funding round for Innate Pharma? Innate Pharma closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are Innate Pharma's competitors? Alternatives and possible competitors to Innate Pharma may include Tango Therapeutics, Avenzo Therapeutics, and  Calidi Biotherapeutics.How much funding has Innate Pharma raised to date? Innate Pharma has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(8c8a01a 1)
|